DRUG · Mapped RxNorm record
Ribociclib
Normalized identity: ribociclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
NCT03078751
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Adjuvant endocrine therapy
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAdjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
DallasTexas, United States2TacomaWashington, United States2HoustonTexas, United States1Los AngelesCalifornia, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1NashvilleTennessee, United States1DenverColorado, United States1CharlotteNorth Carolina, United States1TucsonArizona, United States1Kansas CityMissouri, United States1FairfaxVirginia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03078751 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.